TRAW

NASDAQ 已收盘

Traws Pharma

0.18 USD
▼-0.06-23.91%
盘后 0.17 -5.71%
2026-11-20
市值
$2.69M
市盈率
—
EPS
-1.86
股息率
—
52 周区间
0.17 – 3.23
成交量
381.86K
Beta
1.66
目标价
1.00
52W 低 0.1752W 高 3.23
价格走势

公司简介

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhib...